IRCT20230409057859N1 IRCT 2023-04-18 Shahid Beheshti University of Medical Sciences The effect of L-arginine in non-alcoholic fatty liver Investigating the effect of L-arginine on patients with non-alcoholic fatty liver disease 2023-05-05 anticipated 60 Complete https://irct.ir/trial/69594 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be assigned to two arms, using block randomization method. The block size is four, involving 3 patients (based on order’s coming) which would generated by online block randomization software “Sealed Envelope”. The list of random blocks will be placed in envelopes, daily would be opened by the staffs, Blinding description: The study will be single- blind, so that the analyzing researcher does not know which data is related to which patient, and the data related to the patients will be provided to him with the code, not with the name of the patient. Also, regarding the blinding of the participants, the general process of the study will be explained to them, but the patients will not know which group they will be in and which intervention (placebo or drug). 3 fatty liver. Intervention 1: Intervention group: The first intervention group will receive lifestyle modification and L-arginine drug (Perarin Pars Company) at a dose of 2 grams per day for 3 months. Intervention 2: Intervention group: The second intervention group will receive lifestyle modification and placebo (Perarin Pars Company) once a day for 3 months. No - There is not a plan to make this available Justification or reason for not sharing IPD is Due to the complete presentation of the results based on the data in the text of the article, and the preservation of the raw data, there are no plans to publish it.